Zebra Medical Vision, an Israeli medical imaging analytics company, said on Monday it received its third clearance from the US Food and Drug Administration for its alert for new technology analyzing intracranial hemorrhages.
The latest cleared product, HealthICH, uses artificial intelligence to automatically identify suspected internal brain bleeding based X-rays, CT scans, and MRIs. This can significantly reduce turnaround time and increase the radiologists' confidence in their diagnosis, Zebra said.
Follow Israel Hayom on Facebook and Twitter
Intracranial hemorrhage accounts for about 10% to 20% of all strokes and can occur as a result of traumatic injury, ruptured arteries, stroke or cancer. Its 30-day mortality rate ranges from 35% to 52% with about half occurring in the first 24 hours.
Established in 2014, Zebra Medical uses artificial intelligence and machine learning algorithms for the automated analysis of radiological scans.
Last month, the company announced it had received FDA clearance for its automated chest x-ray triage product that uses deep learning technology to analyze chest x-ray images in order to detect and prioritize lung trauma.
